MicroRNA 17-5p Overexpression Contributes to melanoma cancer metastasis

Abstract

Melanoma is a very aggressive form of skin cancer that spreads swiftly and creates distant metastases. Melanoma early identification and staging can benefit patient treatment. MicroRNA 17-5p is being investigated in this study to determine if it helps distinguish between metastatic and non-metastatic melanoma.. Forty individuals with melanoma diagnosed between 2010 and 2020 were enrolled in this cross-sectional study. Melanoma cell lines isolated from cancer tissue were cultured in the laboratory. The cell lines studied included WM115, BLM, K1735, WM793, and A375M. The concentration of microRNA 17-5p was quantified in real time by polymerase chain reaction. CT scans or chest radiographs were performed to detect metastases in both the control and case groups (n = 20). The levels of microRNA 17-5p were used to distinguish the incidence of metastases. Age and sex of metastatic and non-metastatic patients were similar (P > 0.05). 13 (70%) of metastatic patients had microRNA 17-5p compared to 20% of nonmetastatic patients (P = 0.004). Metastatic patients reported greater levels of microRNA 17-5p (-1.60±1.13)versus (−0.150.67; P = 0.001). MicroRNA 17-5p had an aUC of 0.923, with 100% accuracy and 94.44% specificity (P = 0.001; 95 percent confidence interval: 0.811-1). This study linked malignant melanoma to increased microRNA 17-5p levels. This marker's sensitivity and specificity for detecting metastatic melanoma are 100% and 94.4 percent, respectively.